212 related articles for article (PubMed ID: 19703026)
1. Design, synthesis, and docking studies of peptidomimetics based on HER2-herceptin binding site with potential antiproliferative activity against breast cancer cell lines.
Satyanarayanajois S; Villalba S; Jianchao L; Lin GM
Chem Biol Drug Des; 2009 Sep; 74(3):246-57. PubMed ID: 19703026
[TBL] [Abstract][Full Text] [Related]
2. A conformationally constrained peptidomimetic binds to the extracellular region of HER2 protein.
Banappagari S; Ronald S; Satyanarayanajois SD
J Biomol Struct Dyn; 2010 Dec; 28(3):289-308. PubMed ID: 20919746
[TBL] [Abstract][Full Text] [Related]
3. Design of peptidomimetics for inhibition of HER2 receptor dimerization by a combination of virtual screening, MD simulations, and QSAR in silico methods.
Jamalan M; Zeinali M; Barzegari Asadabadi E
Chem Biol Drug Des; 2013 Apr; 81(4):455-62. PubMed ID: 23006820
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3.
Kanthala S; Gauthier T; Satyanarayanajois S
Biopolymers; 2014 Jun; 101(6):693-702. PubMed ID: 24222531
[TBL] [Abstract][Full Text] [Related]
8. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.
Cho HS; Mason K; Ramyar KX; Stanley AM; Gabelli SB; Denney DW; Leahy DJ
Nature; 2003 Feb; 421(6924):756-60. PubMed ID: 12610629
[TBL] [Abstract][Full Text] [Related]
9. Computational analyses of curcuminoid analogs against kinase domain of HER2.
Yim-im W; Sawatdichaikul O; Semsri S; Horata N; Mokmak W; Tongsima S; Suksamrarn A; Choowongkomon K
BMC Bioinformatics; 2014 Aug; 15(1):261. PubMed ID: 25089037
[TBL] [Abstract][Full Text] [Related]
10. Design of cyclic and d-amino acids containing peptidomimetics for inhibition of protein-protein interactions of HER2-HER3.
Pallerla S; Naik H; Singh S; Gauthier T; Sable R; Jois SD
J Pept Sci; 2018 Feb; 24(2):. PubMed ID: 29436155
[TBL] [Abstract][Full Text] [Related]
11. A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer.
Scollard DA; Chan C; Holloway CM; Reilly RM
Nucl Med Biol; 2011 Jan; 38(1):129-36. PubMed ID: 21220136
[TBL] [Abstract][Full Text] [Related]
12. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
13. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
14. In-silico Design, ADMET Screening, MM-GBSA Binding Free Energy of Some Novel Isoxazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer.
Kalirajan R; Pandiselvi A; Gowramma B; Balachandran P
Curr Drug Res Rev; 2019; 11(2):118-128. PubMed ID: 31513003
[TBL] [Abstract][Full Text] [Related]
15. Her2-positive breast cancer: herceptin and beyond.
Dean-Colomb W; Esteva FJ
Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
[TBL] [Abstract][Full Text] [Related]
16. Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance.
Gu L; Waliany S; Kane SE
PLoS One; 2009 Jul; 4(7):e6220. PubMed ID: 19593441
[TBL] [Abstract][Full Text] [Related]
17. Comparative anti-proliferative effects of potential HER2 inhibitors on a panel of breast cancer cell lines.
Zalloum H; AbuThiab T; Hameduh T; AlBayyari S; Zalloum W; Abu-Irmaileh B; Mubarak MS; Zihlif M
Breast Cancer; 2020 Mar; 27(2):213-224. PubMed ID: 31559601
[TBL] [Abstract][Full Text] [Related]
18. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
Chen KT; Lee TW; Lo JM
Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
[TBL] [Abstract][Full Text] [Related]
19. Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.
Ghedini GC; Ciravolo V; Tortoreto M; Giuffrè S; Bianchi F; Campiglio M; Mortarino M; Figini M; Coliva A; Carcangiu ML; Zambetti M; Piazza T; Ferrini S; Ménard S; Tagliabue E; Pupa SM
J Cell Physiol; 2010 Oct; 225(1):256-65. PubMed ID: 20506359
[TBL] [Abstract][Full Text] [Related]
20. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]